Innovation Articles

  1. Pharmacogenomics In Oncology: A Pharmacokinetic Perspective 7/22/2026

    The outcome of a medical treatment is not solely determined by the efficacy of the drug itself. It also depends on the patient’s genetic makeup, biological characteristics of the disease, and individual clinical factors.

  2. From Valency To Vaccine Design: The Changing Competitive Landscape In Pneumococcal Vaccines 7/21/2026

    Pneumococcal vaccination remains one of the strongest success stories in bacterial disease prevention, but the residual burden is now posing new challenges. 

  3. Rhogam's Unconventional History And Why There Is No True Synthetic Replacement (Part 2 of 3) 7/17/2026

    Rhogam transformed Rh disease prevention, but its plasma-derived, polyclonal biology has resisted decades of synthetic anti-D replacement efforts.

  4. Can We Cure Diabetes? 7/15/2026

    We caught up with Minutia CEO Katy Digovich to discuss engineered iPSC-derived islets intended for transplantation into the forearm, which could make a functional cure for insulin-dependent diabetes broadly accessible.

  5. The Next Chapter Of Obesity And Type 2 Diabetes Care: ADA 2026 Signals A More Personalized Future 6/23/2026

    The American Diabetes Association 2026 conference showed where we are and where we're going with GLP-1 therapies.

  6. 2026 Nucleate Boston Activator Cohort Interview: Dr. Chathuraka Jayasuriya — EnkaBio 6/11/2026

    Dr. Chat Jayasuriya discusses EnkaBio’s meniscus repair therapy, fundraising, Nucleate’s impact, CEO search, and tech transfer from Brown/Rhode Island Hospital.

  7. 2026 Nucleate Boston Activator Cohort Interview: Chris Clifford — Mimic Therapeutics 6/10/2026

    Chris Clifford, founder of Mimic Therapeutics, describes the company’s mission as protecting cell therapies from immune rejection, with an initial focus on Type 1 diabetes.

  8. Strategic Synthesis Of ASGCT And ASCO 2026 6/10/2026

    The spring 2026 conference season made one thing obvious to those of us watching the data: the artisan era of ex vivo cellular manufacturing is finally receding.

  9. 2026 Nucleate Boston Activator Cohort Interview: Michael Cronce — Omni Therapeutics 6/9/2026

    Omni Therapeutics is developing first-in-class nucleotides from a novel immune metabolite, using Nucleate support to advance colorectal cancer programs.

  10. A New De Novo Protein Design Platform For GPCR Drug Discovery 6/9/2026

    Skape Bio and UW created an AI-driven platform to design miniproteins that modulate GPCRs in living cells, opening new paths for biologic drug discovery.